Contributions
Abstract: PB2389
Type: Publication Only
Background
Aplastic anemia is an immune-mediated bone marrow failure syndrome that impairs the quality of patients’ life greatly and immunosuppressive therapy is one of the effective treatment. Few studies have been conducted on the quality of life of AA patients.
Aims
To explore the change of quality of life (QoL) in non-severe aplastic anemia (nSAA) patients before and after 2 years of cyclosporine A therapy, and the possible factors which may affect the QoL.
Methods
Patients with de novo non-severe AA from Jan,2014 to Jan, 2016 who had been treated with only cyclosporine A (CsA) for at least 2 years in the out clinic of Peking Union Medical College Hospital were asked to fill-in the SF36 form before and after CsA treatment. Data from nSAA were compared with those of normal controls and patients’ information like age, sex, education, annual income, insurance type, compliance were collected, disease severity and treatment effect were also evaluated.
Results
52 patients were included in our study with 27（51.9%）males and 25（48.1%）females. The medium age were 48-year-old（21 ~85 year-old）. After two years of treatment, 15（28.8%） patients achieved CR， 25（48.1%） achieve PR and 12 （23.1%） patients had no effects (NR)，The overall response（ORR）were 76.9%。Before therapy, the scores of SF36 in nSAA patients were significantly lower than that of normal controls either in physical or mental component summaries（P＜0.05）. After 2 years of therapy, however, nSAA patients had significant improvement of mental component summaries and recovered to normal with even higher score in VT and MH compared with normal controls, although they still had lower scores in physical component summaries compared with normal ones. No associations were found between QoL and age, sex, education level, family income, type of payment, adherence of patients, or severity of disease onset. Patients with CR and PR had shown significant improvement in QoL.
Conclusion
Patients wih nCAA had impaired QoL compared with normal. Treatment of CsA can improved the QoL, especially in mental component summaries. Patients can benefit from the treatment regardless of their social statues or severity of disease and patients need to achieve at least PR to see significant improvement.
Session topic: 36. Quality of life, palliative care, ethics and health economics
Keyword(s): Aplastic anemia, Cyclosporin A, Quality of Life
Abstract: PB2389
Type: Publication Only
Background
Aplastic anemia is an immune-mediated bone marrow failure syndrome that impairs the quality of patients’ life greatly and immunosuppressive therapy is one of the effective treatment. Few studies have been conducted on the quality of life of AA patients.
Aims
To explore the change of quality of life (QoL) in non-severe aplastic anemia (nSAA) patients before and after 2 years of cyclosporine A therapy, and the possible factors which may affect the QoL.
Methods
Patients with de novo non-severe AA from Jan,2014 to Jan, 2016 who had been treated with only cyclosporine A (CsA) for at least 2 years in the out clinic of Peking Union Medical College Hospital were asked to fill-in the SF36 form before and after CsA treatment. Data from nSAA were compared with those of normal controls and patients’ information like age, sex, education, annual income, insurance type, compliance were collected, disease severity and treatment effect were also evaluated.
Results
52 patients were included in our study with 27（51.9%）males and 25（48.1%）females. The medium age were 48-year-old（21 ~85 year-old）. After two years of treatment, 15（28.8%） patients achieved CR， 25（48.1%） achieve PR and 12 （23.1%） patients had no effects (NR)，The overall response（ORR）were 76.9%。Before therapy, the scores of SF36 in nSAA patients were significantly lower than that of normal controls either in physical or mental component summaries（P＜0.05）. After 2 years of therapy, however, nSAA patients had significant improvement of mental component summaries and recovered to normal with even higher score in VT and MH compared with normal controls, although they still had lower scores in physical component summaries compared with normal ones. No associations were found between QoL and age, sex, education level, family income, type of payment, adherence of patients, or severity of disease onset. Patients with CR and PR had shown significant improvement in QoL.
Conclusion
Patients wih nCAA had impaired QoL compared with normal. Treatment of CsA can improved the QoL, especially in mental component summaries. Patients can benefit from the treatment regardless of their social statues or severity of disease and patients need to achieve at least PR to see significant improvement.
Session topic: 36. Quality of life, palliative care, ethics and health economics
Keyword(s): Aplastic anemia, Cyclosporin A, Quality of Life